-
Mashup Score: 1Sentinel Lymph Node Biopsy vs No Axillary Procedure in Small Node-Negative Breast Cancer - 15 hour(s) ago
This randomized clinical trial assesses whether the omission of sentinel node biopsy is noninferior to sentinel lymph node biopsy in female patients with small breast cancer and negative results on preoperative ultrasonography of axillary lymph nodes.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14
Whether via the strain of academic advancement or hyper-competitive industry-funded drug-development landscape,1 there has been increasing focus to shift c
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14
Whether via the strain of academic advancement or hyper-competitive industry-funded drug-development landscape,1 there has been increasing focus to shift c
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14
Whether via the strain of academic advancement or hyper-competitive industry-funded drug-development landscape,1 there has been increasing focus to shift c
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14
Whether via the strain of academic advancement or hyper-competitive industry-funded drug-development landscape,1 there has been increasing focus to shift c
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017 - 1 month(s) ago
AbstractBackground. Approximately 40,000 individuals die from metastatic breast cancer each year. We examined what fractions of annual breast cancer-specif
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach | JCO Oncology Practice - 1 month(s) ago
Circulating tumor DNA (ctDNA) refers to DNA fragments released from cancer cells into the bloodstream. Clinical utility of ctDNA in breast cancer has been explored in both metastatic breast cancer (MBC) and early-stage breast cancer (EBC) settings. In MBC,…
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Inferring gender from first names: Comparing the accuracy of Genderize, Gender API, and the gender R package on authors of diverse nationality - 2 month(s) ago
Author summary Gender disparities in academia have prompted researchers to investigate gender gaps in professorship roles and publication authorship. Of particular concern are the gender gaps in cancer clinical trial authorship. Methodologies that evaluate gender disparities in academia often rely on tools that infer gender from first names. Tools that predict gender from first names are often used in methodologies that determine the gender ratios of academic departments or publishing authors in a discipline. However, researchers must choose between different gender predicting tools that vary in their accuracy, ease of use, and cost. We evaluated the binary gender prediction accuracy of Genderize, Gender API, and the gender R package on a gold-standard dataset of 32,968 clinical trialists from around the world. Genderize and Gender API are commercially available, while the gender R package is free and open source. We found that Genderize and Gender API were more accurate than the gende
Source: journals.plos.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Welcome! You are invited to join a webinar: HORMONE RECEPTOR POSITIVE BREAST CANCER. After registering, you will receive a confirmation email about joining the webinar.
Source: us02web.zoom.usCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19With new investments and affiliation agreements, Lifespan to become Brown University Health - 3 month(s) ago
Lifespan and Brown University finalized agreements to expand their longtime affiliation, outlining new financial investments, academic and governance terms, and a new name for Rhode Island’s largest health care system.
Source: www.brown.eduCategories: General Medicine News, Hem/OncsTweet
@OncBrothers @DrHBurstein @JenniferPlichta We are following the #SOUND trial inclusion rigorously. It seems early to color outside the lines, but this is a good step towards right-sized care. Sentinel Lymph Node Biopsy vs No Axillary Procedure in Small Node-Negative Breast Cancer https://t.co/v8mGRDTlfj